Automated Reporting System for Biliopancreatic Endoscopic Ultrasound
Development and Prospective Multicenter Validation of an Automated Reporting System for Biliopancreatic Endoscopic Ultrasound
This study aims to develop and prospectively validate an automated reporting system to generate structured preliminary biliopancreatic EUS reports using information collected before and during EUS examinations. System development will be completed before prospective validation, and patients included in system development will be separate from those enrolled in prospective validation.
The prospective multicenter validation will enroll 420 adults undergoing EUS for suspected or confirmed biliopancreatic disease. Each patient will contribute only the first eligible EUS examination. The primary endpoint is the difference in clinical acceptance rates between system-generated preliminary reports and independently prepared manual preliminary reports. Non-inferiority will be assessed using a predefined margin.
A nested endosonographer-reporting substudy will also compare completion time and quality between final reports prepared by endosonographers with and without assistance of a system-generated preliminary report. The study will assess the ability of automated reporting to support accurate and efficient EUS reporting while routine clinical care remains unchanged.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This study aims to develop and validate an automated reporting system which will generate structured preliminary reports based on preprocedural clinical data, the endosonographer's speech during EUS, EUS videos, and EUS procedural records. System development will be completed before prospective validation, using a dataset separated from the prospective validation cohort.
The prospective multicenter validation will enroll 420 adults undergoing EUS for suspected or confirmed biliopancreatic diseases. Each patient will contribute only the first eligible EUS examination as the index EUS examination. For each index examination, the automated reporting system will generate a system-generated preliminary report, while the examining endosonographer will independently generate the manual preliminary report without AI assistance. Additionally, speech-only preliminary reports and video-only preliminary reports will be generated to explore the contribution of different data inputs.
Each report will be independently assessed by two EUS experts blinded to the report source. Disagreements between the two assessors will be adjudicated by a third expert. Significant clinical corrections are defined as corrections to errors or omissions that could affect lesion localization, diagnosis, or subsequent clinical management; word and format changes alone do not qualify as significant clinical corrections. Clinical acceptance rate is defined as the proportion of all reports generated for enrolled patients that were accepted without significant clinical corrections. The primary endpoint is the difference in clinical acceptance rates between the system-generated preliminary report and the manual preliminary report of the same patient.
Additionally, a predefined nested endosonographer-reporting substudy will use the same cases to compare completion time and quality between final reports prepared by endosonographers with and without assistance of a system-generated preliminary report. Reporting tasks will be randomly assigned to endosonographers. This substudy will evaluate whether the automated reporting system can improve reporting efficiency while maintaining final report quality.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Zhen Li
- Numero di telefono: 86+18560086106
- Email: qilulizhen@sdu.edu.cn
Luoghi di studio
-
-
Shandong
-
Jinan, Shandong, Cina, 250012
- Qilu Hospital of Shandong University
-
Contatto:
- Zhen Li
- Numero di telefono: 86+18560086106
- Email: qilulizhen@sdu.edu.cn
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Adults undergoing EUS for suspected or confirmed biliopancreatic disease at participating hospitals.
Descrizione
Inclusion Criteria:
- Patients aged ≥ 18years;
- Patients undergoing EUS for suspected or confirmed biliopancreatic disease;
- Patients who voluntarily sign the informed consent.
Exclusion Criteria:
- Patients who are unable to complete standard scanning due to gastrointestinal obstruction or other reasons;
- Patients who underwent surgical treatment or anatomical alterations of the pancreas due to lesions in other thoracic and/or abdominal organs, as well as patients with congenital anatomical abnormalities;
- Patients undergoing EUS primarily for therapeutic purpose such as drainage.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Adults undergoing biliopancreatic endoscopic ultrasound
Adults undergoing EUS for suspected or confirmed biliopancreatic diseases will participate in this study. Each patient provides only the first eligible EUS examination for a prospective validation of the automated reporting system. |
The system that integrates preprocedural clinical data, the endosonographer's speech during EUS, EUS videos, and EUS procedural records to generate a system-generated preliminary report. The system-generated preliminary report is generated for research validation after the routine EUS examination and is compared with the endosonographer's independent manual preliminary report. The system does not determine the patient's clinical care. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Difference in clinical acceptance rates between system-generated and manual preliminary reports
Lasso di tempo: Preliminary reports from the index EUS examination; assessment within 60 days after EUS.
|
The within-patient paired difference in clinical acceptance rates, calculated as the rate for system-generated preliminary reports minus that for independently written manual preliminary reports. A report is accepted if it requires no significant clinical corrections-corrections to errors or omissions that could affect lesion localization, diagnosis or clinical management. Failed or blank system-generated reports are classified as not accepted. Non-inferiority is established if the lower limit of the two-sided 95% confidence interval is greater than -5 percentage points. |
Preliminary reports from the index EUS examination; assessment within 60 days after EUS.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Completeness of the system-generated preliminary reports
Lasso di tempo: Index EUS examination; report assessment within 60 days.
|
In the prospective paired validation, completeness is the proportion of applicable, reference-confirmed items correctly documented in each system-generated preliminary report. Items cover actual examination extent, organ findings, lesion descriptions, and sampling records. |
Index EUS examination; report assessment within 60 days.
|
|
Number of significant clinical report corrections
Lasso di tempo: Index EUS examination; report assessment within 60 days.
|
In the prospective paired validation, the number of significant clinical corrections required per system-generated preliminary report will be assessed. Reductions and additions relative to the independent manual preliminary report will also be reported. |
Index EUS examination; report assessment within 60 days.
|
|
Reporting time of the system-generated preliminary report
Lasso di tempo: During the first automated report-generation task for the index EUS examination, within 30 days after EUS.
|
In the prospective paired validation, time is measured from submission of all required inputs-including preprocedural clinical data, the endosonographer's speech, EUS videos, and EUS procedure records-to availability of the first system-generated preliminary report. Failed generation will be reported separately. |
During the first automated report-generation task for the index EUS examination, within 30 days after EUS.
|
|
Reporting time of the manual preliminary report
Lasso di tempo: During the routine reporting session immediately after the index EUS examination, up to 60 days
|
Description: In the prospective paired validation, time is measured from the endosonographer beginning routine report preparation to submission of the independent manual preliminary report, without AI assistance. |
During the routine reporting session immediately after the index EUS examination, up to 60 days
|
|
Difference in final report completion time with versus without AI assistance
Lasso di tempo: During the assigned reporting tasks for each index EUS examination, up to 60 days
|
In the randomized endosonographer-reporting substudy, the within-case difference in total time to complete a final report is calculated as unassisted time minus assisted time. Total time includes review of source materials, report generation waiting time where applicable, writing, and verification. This outcome will be formally tested only if non-inferiority of the primary outcome is established. |
During the assigned reporting tasks for each index EUS examination, up to 60 days
|
|
Quality of final reports in the endosonographer-reporting substudy
Lasso di tempo: Final reports from the assigned reporting tasks for each index EUS examination; assessment within 60 days after EUS.
|
In the randomized endosonographer-reporting substudy, the proportion of final reports accepted without significant clinical corrections will be assessed separately for reports completed with and without access to the system-generated preliminary report. Completeness and clinically important errors and omissions will also be reported. |
Final reports from the assigned reporting tasks for each index EUS examination; assessment within 60 days after EUS.
|
Collaboratori e investigatori
Pubblicazioni e link utili
Pubblicazioni generali
- Figueroa RL, Zeng-Treitler Q, Kandula S, Ngo LH. Predicting sample size required for classification performance. BMC Med Inform Decis Mak. 2012 Feb 15;12:8. doi: 10.1186/1472-6947-12-8.
- Nam JM. Establishing equivalence of two treatments and sample size requirements in matched-pairs design. Biometrics. 1997 Dec;53(4):1422-30.
- Julious SA, Campbell MJ, Altman DG. Estimating sample sizes for continuous, binary, and ordinal outcomes in paired comparisons: practical hints. J Biopharm Stat. 1999 May;9(2):241-51. doi: 10.1081/BIP-100101174.
- You H, Tao X, Dong Z, Li Y, Huang L, Li J, Du H, Deng M, Wu Z, Tan X, Yang T, Liu J, Yu H. Artificial intelligence assistance narrows the experience gap in endoscopic reporting of gastric lesions: a prospective clinical trial. Surg Endosc. 2026 Feb;40(2):1651-1660. doi: 10.1007/s00464-025-12410-z. Epub 2025 Dec 4.
- Tango T. Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med. 1998 Apr 30;17(8):891-908. doi: 10.1002/(sici)1097-0258(19980430)17:83.0.co;2-b.
- Jiang R, Chen B, Dong Z, Zeng X, You H, Li Y, Deng Y, Mu G, Wang J, Huang L, Li J, Cheng D, Zhou W, Yu H. Domain specific multimodal large language model for automated endoscopy reporting with multicenter prospective validation. NPJ Digit Med. 2026 Mar 28;9(1):394. doi: 10.1038/s41746-026-02569-7.
- Li X, Yao L, Wu H, Tan W, Zhou W, Zhang J, Dong Z, Ding X, Yu H. A deep learning-based, real-time image report system for linear EUS. Gastrointest Endosc. 2025 Jun;101(6):1166-1173.e11. doi: 10.1016/j.gie.2024.10.030. Epub 2024 Oct 19.
- Bonmati E, Hu Y, Grimwood A, Johnson GJ, Goodchild G, Keane MG, Gurusamy K, Davidson B, Clarkson MJ, Pereira SP, Barratt DC. Voice-Assisted Image Labeling for Endoscopic Ultrasound Classification Using Neural Networks. IEEE Trans Med Imaging. 2022 Jun;41(6):1311-1319. doi: 10.1109/TMI.2021.3139023. Epub 2022 Jun 1.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 2026SDU-QILU-10
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .